Patent intelligence · US
US 9618514
Methods of evaluating patients using E-cadherin and vimentin
Methods of evaluating patients using E-cadherin and vimentin
Patent details — US 9618514
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2017
- Expiration
- Apr 6, 2037
- Applicant
- Agios Pharmaceuticals, Inc.
- Claims
- 32
- CPC classes
- A61K, A61K31/433, A61K38/50
Quick answer
US 9618514 (Methods of evaluating patients using E-cadherin and vimentin) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K31/433, A61K38/50
More from Agios Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428376
Therapeutic compounds and compositions
granted -
US 12377093
Pyruvate kinase activators for use in therapy
granted -
US 12133853
Pyruvate kinase activators for use in treating blood disorders
granted -
US 11957680
Pyruvate kinase activators for use in treating blood disorders
granted -
US 11919915
Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
granted -
US 11878049
Mitapivat therapy and modulators of cytochrome P450
granted -
US 11872225
Pyruvate kinase modulators and use thereof
granted -
US 11866411
Therapeutic compounds and compositions
granted
Frequently asked questions
What is US patent 9618514?
US 9618514 (Methods of evaluating patients using E-cadherin and vimentin) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9618514?
Agios Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.
When does US 9618514 expire?
Our index shows an expiration date of Apr 6, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.